TDSPharm Co

TDSPharm Co Liabilities

The The Liabilities of TDSPharm Co (464280.KQ) as of Oct 30, 2026 is 11.37 B KRW. In the previous year, The Liabilities was 10.66 B KRW — a change of 6.67% (higher).

Liabilities

11.37 BKRW

YoY

6.67%

Last updated:

In 2025, TDSPharm Co's total liabilities amounted to 11.37 B KRW, a 6.67% difference from the 10.66 B KRW total liabilities in the previous year.

The TDSPharm Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
10.82 B KRW
Jan 1, 2022
12.16 B KRW
Jan 1, 2023
11.03 B KRW
Jan 1, 2024
10.66 B KRW
Jan 1, 2025
11.37 B KRW
The TDSPharm Co Liabilities history
YEARLiabilitiesYoY
11.37 BKRW+6.67%
10.66 BKRW-3.35%
11.03 BKRW-9.33%
12.16 BKRW+12.34%
10.82 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing TDSPharm Co's Liabilities

TDSPharm Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating TDSPharm Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing TDSPharm Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

TDSPharm Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in TDSPharm Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about TDSPharm Co stock

The Liabilities of TDSPharm Co is 11.37 B KRW in 2025.

The Liabilities of TDSPharm Co changed from 10.66 B KRW to 11.37 B KRW, representing a 6.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's TDSPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TDSPharm Co

All Key Metrics — TDSPharm Co